Big changes are foreseeable in hormone therapies

Published: 2002-08-16 06:58:00

Updated: 2002-08-16 06:58:00

Market analysts say the domestic hormone therapies market is likely to shrink due to the recent announcement of the U.S. National Institute of Health that combined female hormone preparations is associated with a higher incidence of cerebral apoplexy and myocardial infarction, while the sales of ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK